A global view on prophylaxis: Possibilities and consequences

Haemophilia

Volumn 9, Issue SUPPL. 1, 2003, Pages 10-18

  Shapiro, Amy D ^a  

^a INDIANA HEMOPHILIA AND THROMBOSIS CENTER   (United States)

Author keywords

Developing countries; Haemophilia; On demand therapy; Primary prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING FACTOR CONCENTRATE;

AGE; ARTHROPATHY; ARTICLE; BLEEDING; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; CRYOPRECIPITATE; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; DRUG DOSE REGIMEN; HEALTH CARE; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HEALTH INSURANCE; HEALTH PROGRAM; HEMOPHILIA; HEMOPHILIA A; HUMAN; INFUSION; PATIENT SELECTION; PRIMARY PREVENTION; PRIORITY JOURNAL; RESOURCE ALLOCATION; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 0038102296     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.9.s1.2.x     Document Type: Article

References (50)

1. Ingram GI, Evans DI. The history of haemophilia. Haemophilia 1997; 3 (Suppl. 1): 5-15.
2. Ljung R, Aronis-Vournas S, Kurnik-Auberger K et al. Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries. Haemophilia 2000; 6: 619-24.
3. Shapiro AD, Donfield SM, Lynn HS et al. Defining the impact of hemophilia: the academic achievement in children with hemophilia study. Pediatrics 2001; 108: E105.
4. Gruppo RA. Prophylaxis for hemophilia: state of the art or state of confusion? J Pediatr 1998; 132: 915-7.
5. Smith PS, Teutsch SM, Shaffer PA, Rolka H, Evatt B. Episodic versus prophylactic infusions for haemophilia A: a cost-effectiveness analysis. J Pediatr 1996; 129: 424-31.
6. Nilsson FM, Hedner U, Ahlberg A. Hemophilia prophylaxis in Sweden. Acta Paediat Scand 1976; 65: 129-35.
7. Blanchette VS, Al-Musa A, Stain AM, Ingram J, Fille RM. Central venous access devices in children with hemophilia; an update. Blood Coagul Fibrinolysis 1997; 8 (Suppl. 1): S11-4.
8. Mannucci PM, Mendolicchio L, Gringeri A. Use of prophylaxis to prevent complications of hemophilia. Adv Exp Med Biol 2001; 489: 59-64.
9. Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001; 7: 392-6.
10. Journeycake JM, Quinn CT, Miller KL, Zajac JL, Buchanan GR. Catheter-related deep venous thrombosis in children with hemophilia. Blood 2001; 98: 1727-31.
11. Kessler CM, Gellert GA, Mariani G, Patrick CF. Catalyzing global access to hemophilia care. Thromb Haemost 1995; 73: 896-7.
12. Bird A, Isarangkura P, Almagro D et al. Factor concentrates in the developing world. Haemophilia 1998; 4: 481-5.
13. Srivastava A, Chuansumrit A, Chandy M, Duraiswamy G, Karagus C. Management of haemophilia in the developing world. Haemophilia 1998; 4: 474-80.
14. Srivastava A. Choice of factor concentrates for haemophilia: a developing world perspective. Haemophilia 2001; 7: 117-22.
15. Srivastava A. Delivery of haemophilia care in the developing world. Haemophilia 1998; 4 (Suppl. 2): 33-40.
16. Duraiswamy G. Development of indigenous treatment programs: example of Malaysia. WFH World Forum on Safety and Supply of Haemophilia Treatment Products. Montréal 10-11 April 2000.
17. Jones PM, Boulyjenkov V, eds. Haemophilia care in developing countries. A report of a joint WHO/World Federation of Hemophilia Meeting 16-17 June 1997, Geneva, Switzerland. Haemophilia 1998; 4 (Suppl. 2): 1-66.
18. Chandy M. Ethics of haemophilia care in the developing world. WFH Congress. Haemophilia 2002; 8: 439-40.
19. Evatt BL, Robillard L. Establishing haemophilia care in developing countries: using data to over come the barrier of pessimism. Haemophilia 2000; 6: 131-4.
20. Evatt BL. Public health and international health care development for persons with haemophilia. Operation Improvement and Operation Access. Haemophilia 1998; 4 (Suppl. 2): 54-8.
21. Lusher JM. Prophylaxis in children with hemophilia: is it the optimal treatment? Thromb Haemost 1997; 78: 726-9.
22. The National Hemophilia Foundation. Medical and Scientific Advisory Council (MASAC) recommendations concerning prophylaxis. National Hemophilia Foundation Medical Bulletin 1994, 193.
23. WHO/WFH. Report of a joint WHO/WFH Meeting on the control of haemophilia: Modern treatment of haemophilia, Geneva 21-23 March, 1994, Geneva: WHO.
24. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
25. Fischer K, van der Bom JG, Mauser-Bunschoten EP et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002; 99: 2337-41.
26. Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105: 1109-13.
27. van den Berg HM, Fischer K, Mauser-Bunschoten EP et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112: 561-5.
28. Nilsson IM. Experience with prophylaxis in Sweden. Semin Hematol 1993; 30 (Suppl. 2): 16-9.
29. Kreuz W, Escuriola-Ettingshausen C, Funk M, Schmidt H, Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start? The German experience. Haemophilia 1998; 4: 413-7.
30. Ludlam CA. Treatment of haemophilia. Br J Haematol 1998; 101 (Suppl. 1): 13-4.
31. Santagostino B, Gringeri A, Mannucci PM. State of care for hemophilia in pediatric patients. Paediatr Drugs 2002; 4: 149-57.
32. Schramm W. Experience with prophylaxis in Germany. Semin Hematol 1993; 30 (Suppl. 2): 12-5.
33. Tusell J, Pérez-Bianco R. Prophylaxis in developed and in emerging countries. Haemophilia 2002; 8: 183-8.
34. World Federation of Hemophilia. Report on the WFH Global Survey 2001, 2001.
35. Chuansumrit A, Isarangkura P, Hathirat P. Prophylactic treatment for hemophilia A patients: a pilot study. Southeast Asian J Trop Med Public Health 1995; 26: 243-6.
36. Isarangkura P. Haemophilia care in the developing world: benchmarking for excellence. Haemophilia 2002; 8: 205-10.
37. Ljung R, Kling S, Tedgärd U. The impact of prenatal diagnosis on the incidence of haemophilia in Sweden. Haemophilia 1995; 1: 190-3.
38. Berntorp E. Progress in haemophilic care: ethical issues. Haemophilia 2002; 8: 435-8.
39. Carlsson M, Berntorp, E, Björkman S, Lindvall K. Pharmacokinetic dosing in prophylactic treatment of hemophilia A. Eur J Haematol 1993; 51: 247-52.
40. European self-sufficiency and haemophilia prophylaxis: Achievable goals or idealistic concepts? An accord meeting on the future of haemophilia care. Blood Coagul Fibrinolysis 1994; 5 (Suppl. 4): 55-91.
41. Isarangkura P, Chuansumrit A. Developing and maintaining the hemophilia program in Thailand. Southeast Asian J Trop Med Public Health 1993; 24 (Suppl. 1): 61-5.
42. Petrini P. What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B? Haemophilia 2001; 7: 99-102.
43. Björkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet 2001; 40: 815-32.
44. Björkman S, Shapiro AD, Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia 2001; 7: 133-9.
45. Funk M, Schmidt H, Escuriola-Ettingshausen C et al. Radiological and orthopedic score in pediatric hemophilic patients with early and late prophylaxis. Ann Hematol 1998; 77: 171-4.
46. Pollmann H, Richter H, Ringkamp H, Jürgens H. When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single-centre PUP study. Eur J Pediatr 1999; 158 (Suppl. 3): S166-70.
47. Manco-Johnson MJ, Nuss R, Geraghty S, Funk S, Kilcoyne R. Results of secondary prophylaxis in children with severe hemophilia. Am J Hematol 1994; 47: 113-7.
48. Dzinaj T, Funk M, Schmidt H et al. Radiological score in paediatric hemophilic patients with early and late onset of factor VIII-prophylaxis. Thromb Haemost 1996; 76: 630-1.
49. Aldort LM, Haschmyer RH, Pettersson H, Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor VIII deficient haemophiliacs. J Intern Med 1994; 236: 391-9.
50. Ljung R. Second Workshop of the European Paediatric Network for Haemophilia Management, 17-19 September 1998 in Vitznau/Switzerland. Haemophilia 1999; 5: 286-91.